But utreloxastat had little effect on ALS in the phase 2 trial. PTC powered the study to show whether twice-daily oral dosing ...

Despite the “unfortunate” failure, William Blair analysts do not believe that the utreloxastat readout will heavily affect ...

The announcement means the company will be pulling the plug on the CardinALS trial after its amyotrophic lateral sclerosis ...

PTC Therapeutics (NASDAQ:PTCT) said a Phase 2 placebo-controlled study of its ALS drug candidate utreloxastat failed to meet ...

PTC Therapeutics’ phase 2 CardinALS study of utreloxastat in ALS patients fails to meet primary endpoint: Warren, New Jersey Thursday, November 28, 2024, 15:00 Hrs [IST] PTC The ...

PTC Therapeutics may reeling from the failure of its amyotrophic lateral sclerosis (ALS) drug utreloxastat yesterday, but the ...

PTC Therapeutics' Phase II trial for utreloxastat in ALS failed to meet its primary endpoint, showing no significant ...

PTC Therapeutics (PTCT) announced that the global Phase 2 placebo-controlled CardinALS study did not meet its primary endpoint of slowing ...

Baird analyst Joel Beatty raised the firm’s price target on PTC Therapeutics (PTCT) to $52 from $48 and keeps an Outperform rating on the ...

Utreloxastat was demonstrated to be safe and well tolerated in the CardinALS trial. However, due to the lack of efficacy and biomarker signal, further development is not planned at this time.

Utreloxastat was demonstrated to be safe and well tolerated in the CardinALS trial. However, due to the lack of efficacy and biomarker signal, further development is not planned at this time. PTC is a ...